These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease. Földes J; Takó J; Bános C; Gesztesi E; Varga I Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883 [No Abstract] [Full Text] [Related]
34. Monoclonal antibodies with thyroid stimulating activity, at last. Costagliola S; Vassart G Thyroid; 2002 Dec; 12(12):1039-41. PubMed ID: 12593716 [No Abstract] [Full Text] [Related]
35. A reconsideration of a thyroid-stimulating immunoglobulin as the cause of hyperthyroidism in Graves' disease. McKenzie JM; Zakarija M J Clin Endocrinol Metab; 1976 Apr; 42(4):778-81. PubMed ID: 177449 [TBL] [Abstract][Full Text] [Related]
36. The immunologic basis of Graves's disease. Volpé R N Engl J Med; 1972 Aug; 287(9):463-4. PubMed ID: 5068098 [No Abstract] [Full Text] [Related]
37. Long-acting thyroid stimulator protector assay as a basis for identification of subgroups of Graves' ophthalmopathy. Solomon DH; Chopra IJ; Chopra U; Smith F Trans Assoc Am Physicians; 1976; 89():159-70. PubMed ID: 828344 [No Abstract] [Full Text] [Related]
38. Pathogenesis and therapy of neonatal graves disease. Fisher DA Am J Dis Child; 1976 Feb; 130(2):133-4. PubMed ID: 766612 [No Abstract] [Full Text] [Related]
39. Thyroid-stimulating autoantibodies usually contain only lambda-light chains: evidence for the "forbidden clone" theory. Knight J; Laing P; Knight A; Adams D; Ling N J Clin Endocrinol Metab; 1986 Feb; 62(2):342-7. PubMed ID: 2867105 [TBL] [Abstract][Full Text] [Related]
40. Aetiology of hyperthyroidism. II. Hoffenberg R Br Med J; 1974 Aug; 3(5929):508-10. PubMed ID: 4369764 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]